studies

la/mBC - HER2 positive - 2nd Line (L2), HER inhibitor vs. trastuzumab based treatment, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsHER2CLIMB, 2020 0.66 [0.50; 0.88] LUX-Breast 1, 2016 1.48 [1.12; 1.95] 0.99[0.45; 2.18]HER2CLIMB, 2020, LUX-Breast 1, 2016294%1,120moderatenot evaluable progression or deaths (PFS)detailed resultsHER2CLIMB, 2020 0.54 [0.42; 0.70] HER2CLIMB (patients with brain metastases), 2020 0.48 [0.34; 0.68] LUX-Breast 1, 2016 1.10 [0.86; 1.41] 0.66[0.39; 1.13]HER2CLIMB, 2020, HER2CLIMB (patients with brain metastases), 2020, LUX-Breast 1, 2016390%1,279lownot evaluable objective responses (ORR)detailed resultsLUX-Breast 1, 2016 1.04 [0.71; 1.52] 1.04[0.71; 1.52]LUX-Breast 1, 201610%502NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsHER2CLIMB, 2020 1.92 [0.77; 4.80] 1.92[0.77; 4.80]HER2CLIMB, 202010%601NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-09-30 13:53 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 317 - treatments: 712,429,903,472,969,902,1321,643,641,640,427,910,430,976,909,966,917,1013,1025,916,977,1029,1017,911,428,971,913,912,918,965,1067,978,915,914,973,974,702,1313,498,1314,368,1301,1412,1298,1299,1334,1332,1303,1325,1320,1305,1300,1429,1324,1335,1307,1322,1319,718,422,1304,421,1312,1326,1368,1373,1309,1302,1308